Safety and Effectiveness of COVIVAC Vaccine Against COVID-19
Author Information
Author(s): Thiem Vu Dinh, Anh Dang Duc, Ha Vu Hai, Van Thom Nguyen, Thang Tran Cong, Mateus Jose, Carreño Juan Manuel, Raghunandan Rama, Huong Nguyen Mai, Mercer Laina D., Flores Jorge, Escarrega E. Alexandar, Raskin Ariel, Thai Duong Huu, Van Be Le, Sette Alessandro, Innis Bruce L., Krammer Florian, Weiskopf Daniela
Primary Institution: National Institute of Hygiene and Epidemiology
Hypothesis
Does the COVIVAC vaccine induce a superior neutralising antibody response compared to the VAXZEVRIA vaccine?
Conclusion
The COVIVAC vaccine is safe and induces a strong immune response, potentially matching or exceeding that of the VAXZEVRIA vaccine.
Supporting Evidence
- Participants receiving COVIVAC had higher neutralising antibody titers compared to those receiving VAXZEVRIA.
- Both doses of COVIVAC were well tolerated with mild side effects.
- Immunogenicity was assessed through neutralising antibody titers at multiple time points.
Takeaway
The COVIVAC vaccine helps your body fight COVID-19 and works just as well, if not better, than another vaccine called VAXZEVRIA.
Methodology
This was a phase 2, randomized, observer-blind trial comparing two doses of COVIVAC to VAXZEVRIA, with participants receiving injections 28 days apart.
Potential Biases
Potential bias due to the unblinded pharmacist and unmasked vaccinators.
Limitations
The study was limited in size and did not evaluate clinical endpoints or the vaccine's effectiveness against variants.
Participant Demographics
Participants included healthy males and non-pregnant females aged 18 and older, with a mean age of 49 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 124.2–189.15 for COVIVAC 3 μg
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website